KRAS and pancreatic adenocarcinoma: In contrast, there was no significant change in cellular morphology or N-cadherin levels in TGFβ-treated Panc02.13 cells, a KRAS wt pancreatic adenocarcinoma cell line, although a slight decrease in the levels of E-cadherin was observed (Figure S2E–H).